Daihan Pharmaceutical Co., Ltd. Overview
Daihan Pharmaceutical is Korea's pioneer manufacturer of intravenous (IV) infusion solutions. The company dates its first IV production to 1953 [S1]. It remains one of three firms that control the domestic basic-IV oligopoly, alongside the JW group (JW Pharmaceutical / JW Life Science) and HK inno.N [S1][S6].
All output comes from one highly automated plant in Ansan. More than 80% of sales go to general and tertiary hospitals [S2-summary][S35].
The economics are unusual for a Korean generic-drug company. Most core basic IVs are designated "exit-prevention drugs" (퇴장방지의약품). This shields them from post-listing price cuts and allows cost-based price-ceiling adjustments [S1]. Scale and automation then delivered operating margins of about 18% for a decade [S8].
The company has no debt and held net cash of KRW 121.4 bn at mid-2026, equal to about 76% of market capitalisation [S1].
Three issues dominate the investment debate:
Concentration: About 68% of revenue comes from IV solutions and almost all sales are domestic.
Thin R&D: R&D spending is about 1% of revenue.
Succession and capital allocation: These questions have kept the stock at about 0.5x book value.
Company's own description
The company says it was founded in 1945 and makes and sells more than 200 pharmaceutical products [S11]. The range covers basic IV solutions, special IV solutions, injectables, OTC drugs, dialysis solutions and quasi-drugs.
It groups activity into four areas [S11]:
Pharmaceutical manufacturing and sale: Prescription drugs are made on sterile parenteral lines that span small-volume ampoules and vials through large-volume infusions and dialysates, plus inhalants and oral forms. OTC sterile liquids include irrigation saline, irrigation water and sodium chloride solution. Quasi-drugs include the "Eye-con" (아이콘액) contact-lens solution.
Exports: of infusions and injectables.
Technology export: This takes the form of plant-related know-how transfer and business partnering.
R&D and quality assurance: The company also states an ambition to extend into manufacturing equipment, medical devices and health-functional products [S11]. No material revenue from these lines was identified.
Independent characterisation
Daihan is a single-site, high-volume sterile-liquids manufacturer. Its economics resemble a regulated utility more than a research-based drug company.
Revenue model. Revenue is almost entirely product sales. Daihan has no subscription or royalty income of note, and its plant-technology transfer income is immaterial and not separately disclosed.
Demand drivers. Core demand is tied to inpatient bed-days. Basic IVs (glucose, saline, electrolyte solutions such as Hartmann's and Darrow's) are consumed per hospital admission. Analysts therefore model volume growth from population ageing and hospital admission days rather than from new-product cycles [S13][S29].
Pricing. Pricing is largely set by the National Health Insurance listing system. Exit-prevention status protects price but caps upside. Price increases require a cost-based application [S1][S13].
Channels. More than 80% of revenue is supplied to hospitals and clinics through the company's own sales network [S35][S2-summary]. Pharmacies are reached for OTC sterile-liquid and lens-care products.
Value-chain position. The company is a vertically integrated formulator and filler. Historically it also made its own containers (it set up an IV glass-bottle works in 1953) [S11]. It has in-house capability for about 20 active pharmaceutical ingredients, built after the central research institute opened in 1987/88 [S31].
Key purchased inputs. These are bulk chemicals (glucose, salts, amino acids) and polymer packaging (non-PVC bags, PP bottles, ports and caps). Packaging and components are estimated at 30–40% of IV production cost [S7].
End-markets and customers:
-
Hospital inpatient care (general and tertiary hospitals): fluid replacement and electrolyte balance.
-
Parenteral nutrition: amino acid solutions and a small three-chamber TPN position.
-
Anaesthesia and surgery: local anaesthetics in ampoules, irrigation solutions.
-
Renal care: dialysis solutions.
-
Retail pharmacy: sterile saline and lens-care.
Strategy
Stated strategy. Daihan does not publish a formal medium-term plan or investor-day material. Its strategy can be read from filings, press and actions [S8][S9][S35]:
-
Stay concentrated on IVs and injectables, reinvesting profits in production infrastructure (automation, warehousing) rather than diversifying. Management treats facilities and process as the competitive moat in an equipment-intensive industry [S8].
-
Ageing-linked volume growth: basic-IV demand tracks inpatient days and the elderly population [S13][S35].
-
Cost discipline: keeping cost of sales at about 66% and SG&A at about 15% of revenue historically [S35]; both ratios worsened in FY2025.
-
Capacity expansion: a new plant is planned on 3,000 pyeong of the expansion site, described as supporting growth "including global business" [S9]. Timing, budget and products are not disclosed.
-
Higher-value nutrition: the three-chamber TPN entry (Tetraprof), launched after 2021 approval, with a non-reimbursed-first, reimbursement-later strategy [S28][S20]. KIR identifies nutritional-IV growth as a re-rating lever [S1].
-
Shareholder returns: DPS raised four years in a row (KRW 400 → 1,000), a KRW 3 bn buyback in 2022, and owner open-market purchases [S12][S15][S30-2].
Initiatives in the last 24 months:
-
Automated-warehouse completion (May 2024) and line upgrades; FY2025 capex of KRW 25.1 bn [S4].
-
Designation as a Supply-Stability Leading Company (1 Aug 2026 – 31 Jul 2027). This gives a 50% (instead of 45%) price-calculation rate on new generic listings for up to 1+3 years if domestically produced [S10][S-dailypharm 341047].
-
Supply management through the naphtha shock, supported by government priority allocation of naphtha to IV bags [S6][S7].
ESG or cost programmes with targets: none disclosed.
Medium-term financial targets or guidance: not publicly disclosed. The company does not issue guidance. The KIR FY2026 estimate (revenue KRW 220.0 bn; OP KRW 29.5 bn; NI KRW 25.0 bn) is a third-party forecast [S1].
Products & Services
The company website lists 99 products in its searchable catalogue across prescription, OTC and quasi-drug categories [S11-products]. It describes the overall range as about 200 finished products [S11]. Product-level revenue and pricing are not publicly disclosed.
The table below lists named products identified in public sources. It is not exhaustive.
Basic and electrolyte IV solutions (core; exit-prevention-drug heavy)
| Product | Description | Target / use | Notes |
|---|---|---|---|
| Daihan 10% Dextrose in Saline (대한10%포도당가생리식염액) | Dextrose-saline maintenance fluid | Hospital inpatients | Catalogue item [S11-products] |
| Daihan 20% Dextrose Injection (대한20%포도당주사액) | Concentrated glucose | Caloric supplementation | Catalogue item [S11-products] |
| Daihan Plascon Inj. (대한플라스콘주) | Multi-electrolyte solution suited to extracellular fluid (ECF) replacement | Peri-operative, ICU | Featured product [S11] |
| Hartmann's and Darrow's solutions | Electrolyte IVs | Fluid and electrolyte replacement | Historic core range since 1977 [S11][S1] |
| Inveton (인베톤) | Invert-sugar IV | Energy supply | Developed 1959 [S11] |
| Multiplex Peri (멀티플렉스페리) 550/1,100 mL | Peripheral IV in multi-port bag | Peripheral nutrition/fluids | Product gallery [S11-gallery] |
| Formats | Non-PVC bags (500/1,000 mL), PP bottles, Flumat-port bags, PE Bottle-Pack | — | [S11-gallery] |
Nutritional IV solutions
| Product | Description | Target | Launch / status |
|---|---|---|---|
| Armix Inj. (아르믹스주) | Complete amino-acid solution optimised for TPN compounding | Hospital pharmacies, ICU | Featured product [S11] |
| Nutrihex Inj. (뉴트리헥스주) | Nutritional infusion | Hospital | Catalogue [S11-products] |
| Nephrisol Inj. (네프리솔주) | Renal-type amino-acid infusion (by name) | Renal patients | Catalogue [S11-products] |
| Glypurol Inj. (글리푸롤주) | Glycerol-based infusion (by name) | Hospital | Catalogue [S11-products] |
| Tetraprof Inj. / Tetraprof Peri Inj. (테트라프주/테트라프페리주) | Three-chamber lipid/amino-acid/glucose TPN; generic of SMOFKabiven / Peripheral | Central and peripheral parenteral nutrition | MFDS approval Sep 2021. Launch was delayed because reimbursement listing was not obtained [S20][S28]. A non-reimbursed launch was reported for the year before Dailypharm's 2022 article [S34]; commercial scale not disclosed. A higher omega-3 version was reportedly planned [S-dailypharm 2023-12]. |
Ampoules and vials (small-volume parenterals)
| Product | Description | Notes |
|---|---|---|
| Lidocaine HCl hydrate Inj. 20 mL (리도카인염산염수화물주) | Local anaesthetic, PP ampoule | Export version for Hong Kong noted in the product gallery [S11-gallery] |
| Bonorex 300/350 Inj. (보노렉스) | Contrast-medium-type injection (by naming) | Product gallery [S11-gallery] |
| Anaesthetic and contrast media ranges | Grouped in the product gallery | [S11-gallery] |
| 20 mL PP ampoules | Plastic ampoule format | [S11-gallery] |
Other prescription products
| Category | Examples / notes |
|---|---|
| Oral solids | Gamofree Tab. (가모프리정, mosapride citrate) [S11-products] |
| Dialysis solutions | Haemodialysis/peritoneal dialysates (product gallery "투석액") [S11-gallery] |
| APIs | In-house APIs (about 20 technologies) [S31] |
| Inhalants, antibiotics, hormones, antidotes, sedatives, analgesics | Listed by an aggregator profile [S-roic]; not individually verified |
OTC and quasi-drugs (pharmacy channel)
| Product | Description |
|---|---|
| Daihan Sterile Saline for Irrigation (대한관류용멸균생리식염) | Sterile irrigation saline (OTC) [S11] |
| Daihan Sterile Water for Irrigation (대한관류용멸균증류수) | Sterile irrigation water [S11] |
| Daihan Sodium Chloride Solution (대한염화나트륨액) | Sterile NaCl solution [S11] |
| Daihan Sterile Saline 10 mL (대한멸균생리식염수) | Featured product [S11] |
| Eye-con (아이콘액) | Contact-lens cleaning solution (quasi-drug) [S11] |
Pricing model. Prescription products are sold at or below National Health Insurance (NHI) ceiling prices. Exit-prevention products are excluded from actual-transaction price cuts [S-MOHW 2025] and can apply for cost-preservation ceiling increases [S1]. OTC and quasi-drug pricing is not disclosed.
Financial Narrative
Income statement
Sources: annual figures from Butler/DART [S5], confirmed by the FY2025 earnings disclosure [S27] and KIR [S1]. EPS is derived as NI ÷ 6.0 M issued shares, the basis used by ValueLine [S2]. DART EPS uses weighted shares excluding treasury stock and will be about 2% higher. DPS is from LS Securities [S12] and dividend records [S15].
Revenue CAGR FY2021–FY2025: about 5.0% a year. Since the 1994 listing, KIR calculates average revenue growth of 8.8% a year with no operating loss in 32 years [S1].
Diluted EPS: No convertible or warrant instruments were identified, so diluted EPS equals basic EPS.
FY2025 detailed P&L. ValueLine's FY2025 column and its TTM to March 2025, used as an FY2024 proxy, give the following [S2]:
Quarterly trajectory (derived). Quarterly figures for 2024 come from LS Securities [S12]. Quarters for 2025 and 2026 are back-calculated from ValueLine TTM series [S2] and reconcile to the reported 9M2025 OP of KRW 27.6 bn [S8] and FY2025 totals.
H1 2026 (derived): revenue of about KRW 109.3 bn (+7.8% YoY) and operating income of about KRW 15.9 bn (-6% YoY), for an operating margin of about 14.6%. The half-year report was filed on 14 Aug 2026 [S5].
Commentary — growth. FY2021–FY2024 was a clean volume-led recovery from the COVID-19 trough, with 12 straight quarters of YoY revenue growth to Q1 2024 [S13]. Brokers attribute the growth almost entirely to quantity (Q). Exit-prevention status prevented price cuts, but health-insurance budget constraints also prevented price rises [S13][S21-1Q23].
In FY2025, IV revenue declined 9% [S6]. Total revenue still edged up 2.2%, helped by the "other" category (see §4.2 on comparability).
Commentary — the FY2025 margin inflection. Operating margin fell 3.7 pp to 15.0%, the lowest level in at least five years. Four drivers stand out:
-
Labour inflation: cost-of-sales labour was up about KRW 3.8 bn versus the FY2024 proxy.
-
Depreciation step-up: about +KRW 1.8 bn in cost of sales. In FY2025, construction-in-progress of KRW 18.2 bn moved into structures and machinery, reflecting the automated-warehouse and line investments [S3].
-
Raw-material cost creep.
-
Negative operating leverage on lower IV volumes during the medical crisis [S6].
Q4 2025 was exceptionally weak, with an operating margin of about 7%. The sources do not disclose the specific cause. Possible explanations include year-end bonuses, retirement-benefit charges, inventory adjustments, or one-off costs.
Commentary — 2026. H1 2026 revenue recovered as hospital volumes normalised after the medical crisis officially ended in October 2025 [S6]. Margins, however, stayed compressed at about 14–15%. The Middle East conflict pushed naphtha prices up by about 50%, raising IV-bag and component costs; packaging is 30–40% of IV cost [S7]. KIR forecasts FY2026 OP of KRW 29.5 bn (operating margin 13.4%) on revenue of KRW 220.0 bn [S1].
Balance sheet
Source: ValueLine (DART stand-alone) [S3].
Net cash. KIR puts net cash at KRW 121.4 bn at end-June 2026: cash equivalents of KRW 59.6 bn plus deposit-type financial assets of KRW 61.8 bn, equal to about 76% of market capitalisation [S1].
At FY2025, other current assets of about KRW 42.5 bn appear to be short-term deposits classified outside "short-term financial instruments." Including these, cash-like assets were about KRW 90 bn at Q3/Q4 2025. This matches press reports of cash near KRW 90 bn [S8].
The apparent fall in "cash" from FY2023 to FY2025 therefore mainly reflects reclassification into term deposits and investment assets, plus capex, rather than cash burn.
Debt. Borrowings fell to zero during 2023. Dailypharm reported the decline as KRW 16.7 bn to zero [S20-rel]. Year-end FY2022 borrowings per ValueLine were KRW 6.5 bn [S3], so the 16.7 bn peak was at an intra-year point. The balance sheet has been debt-free since FY2023.
Retained earnings of KRW 308.3 bn (1H2026) make up essentially all of equity. Share capital is KRW 3.0 bn [S3].
Cash flow
Source: ValueLine [S4].
Commentary. FY2025 FCF was almost nil for two reasons:
-
Capex peaked with completion of the automated-warehouse and line investments.
-
Working capital absorbed KRW 13.4 bn. Inventory rose KRW 8.1 bn, consistent with weaker IV sell-through during the medical crisis and possibly pre-buying of packaging.
TTM cash conversion has since recovered: OCF of KRW 37.3 bn and FCF of about KRW 20 bn. Historically, annual OCF has run at "KRW 30-odd bn" [S35].
The company has about 5,000 pyeong of land. Of this, 2,000 pyeong is already built out as an automated warehouse, and a new plant is planned on the remaining 3,000 pyeong [S8][S9]. This implies a further capex wave, whose timing and budget are not publicly disclosed.
Ratios
Commentary. Returns are healthy on operating capital: ROIC is about 15% even after the FY2025 margin dip. Reported ROE and ROA, however, are diluted by surplus cash of roughly 40% of equity. This underpins the market's P/B discount and the push from KIR and Dailypharm for buybacks and cancellation, a higher payout, or growth investment [S1][S9].
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
IV solutions revenue (KRW Bn) | 151.2 | 156.5 | 142.7 |
Total revenue (KRW Bn) | 195.9 | 204.2 | 208.6 |
Non-IV revenue, derived (KRW Bn) | 44.7 | 47.7 | 65.9 |
IV share of revenue (%) | 77.2 | 76.6 | 68.4 |
IV revenue YoY growth (%) | — | 3.5 | -8.8 |
Basic IV % by Period
| Period | Basic IV % | Nutritional IV % | Ampoule & vial % | Other products % | Source |
|---|---|---|---|---|---|
FY2024 (broker figure) | — | 13.4 | — | — | LS Securities [S12] |
FY2025 | 56 | 12 | 6 | 26–27 | Employer registry citing filings [S14] |
Q2 2026 | 76 | 16 | 8 | not shown | Butler [S5] |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 171.5 | 184.3 | 195.9 | 204.2 | 208.6 |
Operating income (KRW Bn) | 29.1 | 33.0 | 35.8 | 38.1 | 31.2 |
Net income (KRW Bn) | 22.7 | 25.0 | 28.4 | 33.8 | 27.6 |
Revenue growth YoY (%) | 1.5 | 7.5 | 6.3 | 4.2 | 2.2 |
Operating margin (%) | 17.0 | 17.9 | 18.3 | 18.7 | 15.0 |
Net margin (%) | 13.2 | 13.6 | 14.5 | 16.6 | 13.2 |
EPS, derived (KRW) | 3,783 | 4,167 | 4,733 | 5,633 | 4,607 |
DPS (KRW) | 400 | 650 | 750 | 900 | 1,000 |
Payout ratio, derived (%) | 10.6 | 15.6 | 15.8 | 16.0 | 21.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (TTM to Mar-2025 (FY2024 proxy)–TTM to Jun-2026)
| Line item (KRW Bn) | TTM to Mar-2025 (FY2024 proxy) | FY2025 | TTM to Jun-2026 |
|---|---|---|---|
Revenue | 205.1 | 208.6 | 216.6 |
Cost of sales | 135.6 | 143.8 | 152.4 |
– of which raw materials | 70.9 | 73.4 | 76.0 |
– of which labour | 37.8 | 41.6 | 42.8 |
– of which depreciation | 6.9 | 8.7 | 11.1 |
Gross profit | 69.2 | 64.8 | 64.1 |
Gross margin (%) | 33.7 | 31.1 | 29.6 |
SG&A | 32.6 | 33.6 | 34.0 |
– freight | 8.0 | 8.1 | 8.3 |
– R&D expense | 2.2 | 2.2 | 1.7 |
Operating income | 37.2 | 31.2 | 30.1 |
EBITDA | 45.1 | 40.5 | 42.6 |
Pre-tax income | 39.2 | 33.2 | 32.9 |
Income tax | 7.9 | 5.5 | 5.4 |
Net income | 31.3 | 27.6 | 27.5 |
Financial Analysis
| Metric | Q1-24 | Q2-24 | Q3-24 | Q4-24 | Q1-25 | Q2-25 | Q3-25 | Q4-25 | Q1-26 | Q2-26 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 49.0 | 48.9 | 54.8 | 51.4 | 49.9 | 51.5 | 56.1 | 51.1 | 52.7 | 56.6 |
Operating income (KRW Bn) | 10.1 | 8.4 | 10.8 | 8.7 | 9.2 | 7.7 | 10.6 | 3.6 | 7.9 | 8.1 |
Operating margin (%) | 20.6 | 17.2 | 19.7 | 16.9 | 18.4 | 15.0 | 18.9 | 7.0 | 15.0 | 14.3 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | 1H2026 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | 277.0 | 294.3 | 324.4 | 347.7 | 359.3 |
Cash & equivalents (KRW Bn) | 90.9 | 101.5 | 61.3 | 44.0 | 59.6 |
Short-term financial instruments (KRW Bn) | 6.8 | 2.9 | 8.9 | 4.0 | 55.1 |
Non-current investment assets (KRW Bn) | 7.4 | 8.1 | 52.2 | 35.3 | 23.9 |
Trade receivables (KRW Bn) | 31.3 | 30.9 | 31.2 | 31.0 | 29.6 |
Inventories (KRW Bn) | 24.9 | 23.6 | 26.7 | 33.9 | 36.3 |
PP&E (KRW Bn) | 113.2 | 125.9 | 134.4 | 153.4 | 151.3 |
Goodwill & intangibles (KRW Bn) | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
Short-term borrowings (KRW Bn) | 2.5 | 0.0 | 0.0 | 0.0 | 0.0 |
Long-term borrowings (KRW Bn) | 4.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total liabilities (KRW Bn) | 51.6 | 46.3 | 48.4 | 47.5 | 51.2 |
Shareholders' equity (KRW Bn) | 225.4 | 248.0 | 276.0 | 300.2 | 308.1 |
Current assets (KRW Bn) | 155.9 | 159.9 | 137.4 | 158.5 | 183.5 |
Current liabilities (KRW Bn) | 42.7 | 41.3 | 42.6 | 43.5 | 46.2 |
Working capital (KRW Bn) | 113.2 | 118.6 | 94.8 | 115.0 | 137.3 |
Book value per share (KRW) | 37,566 | 41,329 | 45,999 | 50,036 | 51,345 |
Cash Flow
| Metric (KRW Bn) | FY2025 | TTM to Jun-2026 |
|---|---|---|
Operating cash flow | 25.6 | 37.3 |
Capex (PP&E acquisition) | 25.1 | 17.2 |
Free cash flow (OCF – capex) | 0.5 | 20.2 |
Dividends paid | 5.2 | 5.8 |
Share buybacks | 0.0 | 0.0 |
Change in working capital | -13.4 | -6.7 |
Depreciation (cash-flow basis) | 9.2 | 11.6 |
CAPEX by Year
| Year | Capex (KRW Bn) |
|---|---|
| 2018 | 34.5 (automation peak) |
10-year average to 2018 | 13.9 |
2020–2022 average | 8.6 |
| 2023 | 21.3 |
| 2025 | 25.1 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | Notes |
|---|---|---|---|---|
ROE (%) | 12.0 | 12.9 | 9.6 | NI ÷ average equity; derived |
ROA (%) | 10.0 | 10.9 | 8.2 | NI ÷ average assets; derived |
ROIC (%) | n.c. | n.c. | ~15 | NOPAT (OP × (1 – 16.6% tax)) ÷ (equity – about KRW 126 bn cash-like assets); approximate |
Current ratio (x) | 3.87 | 3.22 | 3.64 | 1H2026: 3.97 |
Debt/equity (x) | 0.00 | 0.00 | 0.00 | FY2022: 0.03 |
Liabilities/equity (%) | 18.7 | 17.5 | 15.8 | 1H2026: 16.6 |
Net debt/EBITDA (x) | net cash | net cash | net cash | Net cash about 2.9x TTM EBITDA (1H2026) |
Asset turnover (x) | 0.69 | 0.66 | 0.62 | Revenue ÷ average assets |
Cash conversion cycle (days) | n.c. | n.c. | ~95 | DSO 54 + DIO 86 – DPO 45; year-end balances; approximate |
Revenue by Region and Revenue by Region (%)
| Metric | FY2021 | TTM Mar-2025 | TTM Jun-2025 |
|---|---|---|---|
Domestic revenue (KRW Bn) | — | 199.6 | 202.3 |
Export revenue (KRW Bn) | — | 5.4 | 5.4 |
Domestic share (%) | 98 | 97.4 | 97.4 |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 30,600 | 27,750 | 26,200 | 29,250 |
Market capitalisation (KRW Bn) | 183.6 | 166.5 | 157.2 | 175.5 |
P/E at year-end, derived (x) | 7.3 | 5.9 | 4.7 | 6.4 |
P/B at year-end, derived (x) | 0.81 | 0.67 | 0.57 | 0.58 |
DPS (KRW) | 650 | 750 | 900 | 1,000 |
Dividend yield at year-end (%) | 2.1 | 2.7 | 3.4 | 3.4 |
Capital Markets
| Metric | Daihan Pharm | JW Life Science |
|---|---|---|
Market cap (KRW Bn) | ~153 | 177.3 [S22] |
P/E TTM (x) | 5.6 [S2] | 6.8 [S22] |
P/B (x) | 0.50 [S2] | 0.78 [S22] |
Dividend yield (%) | ~3.9 [S15] | 4.9 [S22] |
EV, derived (KRW Bn) | ~31 (mkt cap – KRW 121.4 bn net cash) | n.c. |
EV/EBITDA TTM, derived (x) | ~0.7 | n.c. |
EV/Sales TTM, derived (x) | ~0.14 | n.c. |
Analyst Conclusions
Guidance and consensus
Management guidance: none published.
Third-party estimate (KIR, 26 Aug 2026): FY2026 revenue KRW 220.0 bn (+5.5%), OP KRW 29.5 bn (-5.4%; OPM 13.4%), NI KRW 25.0 bn (-9.5%) [S1].
Implied H2 2026: H1 OP of about KRW 15.9 bn (derived) implies H2 OP of about KRW 13.6 bn, consistent with continued packaging-cost pressure.
Earlier forecast missed: LS Securities expected FY2025 OP of KRW 39.5 bn; the actual was KRW 31.2 bn [S12][S5].
Bull case
-
Pricing reset. The policy toolkit has shifted in favour of exit-prevention suppliers: thresholds up 10%, stability bonuses, rapid price increases, and the Supply-Stability Leading Company designation [S25][S10]. HK inno.N's 2.7x increase on 11 items shows the scale possible [S6-rel]. If Daihan wins cost-based increases on high-volume IVs, OPM could return to 17–18%.
-
Volume normalisation plus ageing. H1 2026 revenue was up about 7.8% after the medical crisis ended [S2][S6]. Basic IVs track bed-days in an ageing society [S13].
-
Balance-sheet optionality. Net cash of KRW 121.4 bn (76% of market cap) means EV is about 0.7x EBITDA [S1]. A buyback-and-cancel or a payout step-up, both flagged by KIR as re-rating keys, would unlock value cheaply.
Bear case
-
Structural share loss. IV revenue fell 9% in FY2025 while HK inno.N grew 16%. HK inno.N and JW are winning the high-margin nutrition segment [S6].
-
Cost squeeze without price linkage. Naphtha is up about 50%, packaging is 30–40% of IV cost, and no temporary price-linkage mechanism has been agreed [S7]. Labour and depreciation are also rising [S2].
-
Value trap governance. The family controls about 40%. The CEO holds 6.37% while a gift-tax overhang of KRW 20 bn+ exists. There are no IR briefings, R&D is about 1%, and there is no articulated growth plan [S9][S1].
Catalysts and monitorables (next 12 months)
- Outcome of any temporary IV price-linkage or cost-based ceiling increases for Daihan's exit-prevention items [S7][S25].
Q3 and Q4 2026 operating margins: Is the Q4 2025 trough (about 7%) a one-off?
- Naphtha and packaging cost trends, and the duration of the Middle East disruption [S6].
Capital allocation: any treasury-share cancellation, buyback, or payout policy statement, especially if treasury-cancellation legislation advances.
New-plant capex: announcement for the 3,000-pyeong reserve site [S9].
Succession steps: gift or inheritance transfers between the chairman and the CEO [S9].
TPN traction: Tetraprof reimbursement status and nutritional-IV share [S20].
- Renewal of the Supply-Stability Leading Company status (expires 31 Jul 2027) [S10].
Analyst verdict
Daihan Pharmaceutical is a rare asset in Korean pharma: an essential-medicine manufacturer with real barriers to entry, policy-protected pricing, three decades without an operating loss, and a debt-free balance sheet. Net cash covers about three-quarters of market capitalisation [S1].
The market prices it at about 0.5x book and below 1x EV/EBITDA. That is effectively zero value for a franchise that generated KRW 30–38 bn of operating profit a year over FY2022–FY2025 [S5].
The discount is not irrational, however. FY2025 showed that the moat protects price better than share. Daihan lost about a tenth of its IV revenue while HK inno.N gained, and it still lacks a meaningful foothold in nutrition, where sector growth and margins are concentrated [S6].
Cost inflation from labour, depreciation on recent automation capex, and a geopolitically driven packaging shock has pulled margins into the mid-teens [S2][S7]. Management has offered the market little in response: no guidance, no IR, about 1% R&D, and an unannounced timeline for its next plant [S9].
The investment case is therefore about catalysts rather than the franchise. Three things would change the picture:
Price: Korea's new pro-supply pricing regime converting into concrete ceiling increases for Daihan's high-volume items.
Capital allocation: a credible move such as cancelling treasury stock, a structured buyback, or a higher payout from the KRW 121 bn cash pile.
Growth: a clear nutrition and capacity strategy for the reserve site.
Succession clarity would remove a persistent overhang.
Absent these, the stock is likely to remain a high-yield (≈3.9%), low-volatility cash proxy with modest earnings growth, consistent with KIR's FY2026 forecast of lower profit on higher sales [S1].
On balance, the risk/reward is asymmetric to the upside on valuation grounds: downside is cushioned by net cash, dividends and policy protection. Timing, however, depends on management action that the company has historically been slow to take. Verdict: fundamentally undervalued, catalyst-dependent; monitor pricing outcomes and capital-allocation signals.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Background | Age / birth |
|---|---|---|---|---|
Lee Seung-young (이승영) | President & sole Representative Director | CEO since 3 Apr 2023. Registered director since about 2016/2017; VP in 2021. Joined in 2001/2002 as a supervisor at the Ansan plant. | Economics, SUNY Stony Brook. Rotated through production, quality, facilities, planning and investment. Led the overseas-business team from about 2009. [S8][S32][S30][S11] | About 53 (2026) [S8] |
Lee Yoon-woo (이윤우) | Chairman; largest shareholder | Joined 1969/1970. 5th CEO from 8 Apr 1992 to 3 Apr 2023. | Sungkyunkwan University (Pharmacy); Korea University Graduate School of Business. Chairman of the Korea Pharmaceutical Traders Association (2009). Introduced the Bottle-Pack plastic IV. [S1][S11][S31][S37] | Born 1944 [S1] |
Other registered directors | — | — | As of 2019: Lee Dong-il (sales), Park Young-dae (production), Lim Bang-ho (quality control), Oh Chang-min (finance), Cho Young-ki (accounting) [S-newsthevoice 2019]. | — |
Major Shareholders
| Holder | Stake (%) | As of |
|---|---|---|
Lee Yoon-woo (Chairman) | 24.96 (≈1.50 M shares) | 20 Aug 2026 |
Lee Seung-young (CEO) | 6.37 | 20 Aug 2026 |
Lee Kwang-woo (founder's 2nd son) | 3.75 | 2,025 |
Lee Seung-kyung (nephew) | 1.87 | 2,025 |
Lee Seung-wook (nephew) | 1.87 | 2,025 |
Largest shareholder + 9 related parties (total) | 39.96 (≈2.40 M shares) | 20 Aug 2026 |
Fidelity Management & Research | 8.50 | Jun 2025 (latest public figure; earlier peak 9.99%) |
Mirae Asset Global Investments | 4.97 (fell below the 5% reporting threshold) | Dec 2023 |
Treasury shares | about 2.0 | 2,026 |
Foreign ownership (total) | 20.12 | Aug 2026 |
Major Shareholders by Date
| Date | Stake (%) |
|---|---|
May 2013 | 20.73 |
Apr 2023 | 21.06 |
Dec 2023 | 22.55 |
Jun 2025 | 24.28 |
Jan 2026 | 24.63 |
5 Jun 2026 | 24.75 (1,484,791 shares; bought at KRW 25,988–27,085) |
20 Aug 2026 | 24.96 |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Scale / data | Positioning |
|---|---|---|---|
JW Pharmaceutical (JW중외제약) | Basic, special and nutritional IVs (marketer) | FY2025 consolidated revenue KRW 774.8 bn, OP KRW 93.6 bn [S24]. IV revenue KRW 252.9 bn (2025), of which basic KRW 84.1 bn, special KRW 28.8 bn, nutritional KRW 140.1 bn [S6]. | Market leader in IVs; Winuf TPN franchise |
JW Life Science (JW생명과학) | IV manufacturing arm of the JW group | FY2025 revenue KRW 257.8 bn, OP KRW 33.2 bn [S22]. Mix: TPN 32%, basic 29%, special 26%, haemodialysis 7% (Q2 2026) [S22]. TPN share 54.6% [S-wikidocs JWLS]. | Most direct listed peer |
HK inno.N (HK이노엔, formerly CJ Healthcare) | Basic and nutritional IVs; Osong IV plant | FY2025 revenue KRW 1,063.2 bn, OP KRW 110.9 bn [S23]. IV revenue KRW 141.7 bn (+16%), nutritional KRW 51.0 bn [S6]. | Fast-growing #3, now level with Daihan in IV revenue |
Fresenius Kabi Korea | Three-chamber TPN (SMOFKabiven), IVs | Not publicly disclosed (unlisted subsidiary) | Global originator of Tetraprof's reference product |
Baxter Korea | TPN (Olimel N9E / N12E) | — | Global TPN player [S21] |
MG / WiseMedi (formerly a Yuhan subsidiary) | Three-chamber TPN (Formstna) | — | Niche TPN [S28][S-dailypharm 2024-01] |
Huons; Hana Pharm; Dai Han New Pharm | Small-volume injectables, anaesthetic ampoules | — | Ampoule/vial competition (category overlap; not quantified) |
B. Braun Korea; other importers | Large-volume parenterals | — | Hospital tender competition |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Daihan Pharm | JW Life Science | HK inno.N | JW Pharmaceutical |
|---|---|---|---|---|
Revenue (KRW Bn) | 208.6 | 257.8 | 1,063.2 | 774.8 |
Revenue growth (%) | 2.2 | 15.9 | 18.5 | 7.7 |
Operating income (KRW Bn) | 31.2 | 33.2 | 110.9 | 93.6 |
Operating margin (%) | 15.0 | 12.9 | 10.4 | 12.1 |
IV revenue growth 2025 (%) | -8.8 | — | 16.0 | 2.4 |
R&D intensity (%) | ~1.0 | ~2.5 (9M25) | — | — |



